3-Cl-PCP

# Research Output: 3-Cl-PCP

## Chemical Identity

**Verified via PubChem CID 125502037** [Ref 16 (PsychonautWiki); PubChem database lookup]:

| Field | Value | Source |
|---|---|---|
| IUPAC Name | 1-[1-(3-chlorophenyl)cyclohexyl]piperidine | PubChem CID 125502037 |
| Molecular Formula | C₁₇H₂₄ClN | PubChem CID 125502037 |
| Molecular Weight | 277.8 g/mol | PubChem CID 125502037 |
| InChIKey | HUHBTESMMFLCAN-UHFFFAOYSA-N | PubChem CID 125502037 |
| PubChem CID | 125502037 | API lookup |
| Chemical Class | Arylcyclohexylamine | PubChem CID 125502037 |

**SMILES:** Not returned by PubChem API call; not available in the brief. The canonical SMILES (ClC1=CC=CC(=C1)[C@@]2(CCCC2)N3CCCCC3 or equivalent) can be derived from the IUPAC name but was not directly verified via API. ⚠️ FLAG: Generation agent should retrieve SMILES from PubChem CID 125502037 directly before publishing.

**CAS Number:** Not confirmed via API. Secondary sources (RC vendor listings, PsychonautWiki) do not consistently cite a CAS number. ⚠️ FLAG: CAS number not verified.

**Brief seed data discrepancies:** The brief lists no formula, weight, SMILES, InChIKey, or PubChem CID — all now resolved via PubChem lookup. Pharmacological class listed in the brief (Dopamine receptor ligand, NMDA receptor antagonist, Sigma receptor agonist, Sigma-1 receptor agonist) is consistent with class-level pharmacology but has not been confirmed with substance-specific binding assays for 3-Cl-PCP itself.

---

## Pharmacology

### Mechanism of Action

3-Cl-PCP belongs to the arylcyclohexylamine class, which exerts its primary effects through **non-competitive, use-dependent antagonism of the NMDA receptor** (N-methyl-D-aspartate receptor), specifically binding within the ion channel at the phencyclidine (PCP) binding site Jentsch and Roth (1999 [Ref 10]). This site is only accessible when the channel is open (use-dependence), meaning binding is enhanced by prior glutamate activation. Channel blockade prevents Ca²⁺, Na⁺, and K⁺ flux, disrupting glutamatergic neurotransmission in hippocampus, neocortex, basal ganglia, and limbic system Bey and Patel (2007 [Ref 21]).

Binding at the PCP site has two pharmacologically distinct subtypes: a high-affinity sigma/PCP (σₚ) site and a low-affinity PCP-selective site that is the NMDA channel-associated site. The low-affinity site is enhanced 4–5 fold by glutamate or NMDA agonists and reduced by competitive NMDA antagonists Itzhak (1989 [Ref 12]).

### Receptor Profile (Substance-Specific Data)

**No substance-specific binding affinity (Ki/IC50) data for 3-Cl-PCP has been published in the peer-reviewed literature.** The pharmacological class designation (NMDA antagonist, sigma agonist, dopamine receptor ligand) is inferred from:

1. **Structural analogy with PCP:** 3-Cl-PCP is the 3-chloro ring-substituted analog of PCP, differing only by a chlorine atom at the meta position of the phenyl ring.
2. **In vivo behavioral pharmacology** (Shaw et al. 2024 [Ref 1] — the only published primary study directly testing 3-Cl-PCP).
3. **Class-level receptor binding data** from the parent compound PCP.

**PCP parent compound receptor affinities (for extrapolation):**
- NMDA receptor: Ki ≈ 2 µM (Kapur & Seeman 2002 [Ref 11])
- 5-HT₂ receptor: Ki ≈ 5 µM (Kapur & Seeman 2002 [Ref 11])
- Dopamine D₂ receptor: Ki ≈ 37 µM — with partial agonist activity (Kapur & Seeman 2002 [Ref 11])
- Sigma-1 receptor: PCP has significant but not highly selective sigma-1 affinity (Itzhak & Stein 1990 [Ref 3]; Debonnel & de Montigny 1996 [Ref 2])

**Monoamine reuptake inhibition:** PCP and ketamine inhibit neuronal reuptake of dopamine, norepinephrine, and serotonin at clinically relevant concentrations, producing secondary dopaminergic activation Kohrs and Durieux (1998 [Ref in ketamine review]). This contributes to the stimulant component of PCP-class effects.

**Sigma receptor activity:** PCP demonstrates binding at sigma-1 and sigma-2 receptors (classified in the brief as sigma receptor agonist and sigma-1 receptor agonist). The sigma/PCP site partially overlaps with the NMDA PCP binding site; sigma ligands at these sites modulate glutamatergic and dopaminergic neurotransmission Debonnel and de Montigny (1996 [Ref 2]).

⚠️ **FLAG (Safety-critical):** All receptor binding data for 3-Cl-PCP is inferred from structural analogy with PCP. No published radioligand binding assays for 3-Cl-PCP exist as of the search date (May 2026).

### In Vivo Behavioral Pharmacology (Shaw et al. 2024 [Ref 1]) — PRIMARY EVIDENCE

Shaw et al. (2024 [Ref 1]) is the **only peer-reviewed primary research paper directly studying 3-Cl-PCP**, published in the Journal of Pharmacology and Experimental Therapeutics. This study used adult male NIH Swiss mice (locomotor) and adult male Sprague-Dawley rats (drug discrimination, neurocognitive testing).

Key findings specific to 3-Cl-PCP:

1. **Locomotor stimulation:** Addition of –Cl at the 3-position of the phenyl ring did **not** reduce locomotor effectiveness compared to parent PCP. PCP-like ACXs (including 3-Cl-PCP) were more effective locomotor stimulants than methamphetamine or MDMA in this assay.

2. **Drug discrimination (abuse liability):** 3-Cl-PCP substituted for PCP in a food-reinforced drug discrimination procedure, demonstrating PCP-like interoceptive cues. This is the primary behavioral assay for assessing abuse liability of novel ACXs Balster and Willetts (1988 [Ref 4]).

3. **Psychosis-like neurocognitive effects:** Both PCP and 3-Cl-PCP produced **dose-dependent psychosis-like neurocognitive deficits** in a novel operant assay of rule-governed behavior incorporating attentional set-shifting. Cocaine and morphine did not produce these deficits, demonstrating specificity for the PCP/NMDA antagonist mechanism.

4. **Lethality:** 3-Cl-PCP did **not** produce lethal effects at doses tested in mice — unlike 3-OH-PCP and 3-MeO-PCP (which caused deaths). This distinguishes 3-Cl-PCP from some ring-substituted analogs but does not indicate absence of lethal potential at higher doses.

Pistis (2024 [Ref 20]) provided expert commentary on the Shaw et al. study in the same journal, contextualizing the evolving NPS challenge for novel dissociative analogs.

### Pharmacokinetics (Class-Level Inference from PCP)

No published human pharmacokinetic data exists for 3-Cl-PCP. The following is inferred from PCP parent compound data:

- **Volume of distribution:** 6.2 L/kg (extensive tissue distribution; highly lipophilic) — Cook et al. 1983 [Ref 23]
- **Plasma half-life (PCP):** Mean 17.6 h in 16 subjects; range extends beyond 2 days in some individuals — Cook et al. 1983 [Ref 23]
- **CNS penetration:** Brain levels may reach 9× serum concentration due to high lipophilicity and ion trapping — Bey and Patel 2007 [Ref 21]
- **Protein binding:** High (PCP ~65–80%; extrapolated to 3-Cl-PCP)
- **Hepatic metabolism:** ~90% via oxidative hydroxylation (CYP2B6 primary; CYP2C19, CYP3A4 also involved) — Driscoll et al. 2007 [Ref 14]; Dinis-Oliveira 2017 [Ref 34]
- **Renal excretion:** ~9% of parent compound excreted unchanged; pH-dependent — Perez-Reyes et al. 1982 [Ref 22]; urine acidification increases excretion, alkalinization reduces it
- **Metabolic pathways (PCP):** Hydroxylation of piperidine ring → dihydropyridinium intermediate; para-hydroxylation of phenyl ring → quinone methide intermediate (bioactivation via CYP2B6) — Driscoll et al. 2007 [Ref 14]
- **Entero-hepatic recirculation:** Stomach PCP levels reported at 50× serum concentration — Bey and Patel 2007 [Ref 21]

**Note on 3-Cl-PCP metabolism:** The chlorine substituent at position 3 of the phenyl ring may alter metabolic patterns compared to PCP. The in silico ADME modeling for methoxy-substituted PCP analogs (Jurowski et al. 2026 [Ref 9]) demonstrated CYP3A4, CYP2D6, and CYP2C19 as primary enzymes with O-demethylation as the primary metabolic step. For 3-Cl-PCP, O-dehalogenation is less likely; ring hydroxylation at alternative positions is the expected primary metabolic pathway, but no published data confirms this.

**Brief seed data note:** The brief lists tolerance half-life of 5.5 days (from DB, source: community consensus). This is notably longer than the PCP parent compound plasma half-life. This discrepancy likely reflects tolerance *buildup* rate, not plasma half-life. The DB also notes full reset at 1.5 weeks, consistent with the extended lipophilic redistribution and slow washout of arylcyclohexylamines.

---

## History

**Synthesis and First Appearance:**

3-Cl-PCP was **presumably first synthesized ca. 2020**, with earliest detected provenance traced to a Chinese chemical manufacturing source Tripsitter (2023 [Ref 19]; PsychonautWiki [Ref 16]). It was marketed contemporaneously with 3-F-PCP and DMXE (deschloroketamine analog), representing a wave of novel ring-substituted PCP analogs targeting the research chemical market.

**First forensic detection:** The substance was first formally identified in **December 2020 in Slovenia** by the Slovenian National Forensic Laboratory, documented in a forensic toxicology report coordinated via the EU Early Warning System Tripsitter (2023 [Ref 19]); CFSRE report (2021 [Ref 31]).

**Historical context of ring-substituted PCP analogs:** PCP itself was developed in the 1950s by Parke-Davis as an anesthetic. Numerous ring-substituted analogs were studied in the 1960s–1980s for structure-activity relationships Balster and Willetts (1988 [Ref 4]). The emergence of methoxy-substituted analogs (3-MeO-PCP, 4-MeO-PCP) on the research chemical market beginning around 2011 preceded the chloro-substituted variants by approximately a decade Johansson et al. 2017 [Ref 6].

**Regulatory timeline:**
- December 2020: First identified in Slovenia
- April 2021: Declared illegal in Hungary Tripsitter (2023 [Ref 19])
- March 2026: 3-MeO-PCP permanently placed in DEA Schedule I (providing regulatory precedent) DEA Federal Register (2026 [Ref 18])

No clinical history exists (no therapeutic use, no clinical trials).

---

## Subjective Effects

**No controlled human studies exist for 3-Cl-PCP.** The following is derived from: (1) rodent pharmacology (Shaw et al. 2024 [Ref 1]), (2) class-level data from PCP and closely related analogs, and (3) community/secondary sources.

### From Rodent Pharmacology (Shaw et al. 2024 [Ref 1])

- **Locomotor stimulation:** Robust locomotor stimulant effects in mice, comparable to parent PCP and greater than amphetamines at equivalent doses
- **Dissociative/interoceptive effects:** Full or near-full substitution for PCP in drug discrimination (rats trained to discriminate PCP), indicating similar interoceptive cue profile
- **Cognitive disruption:** Dose-dependent impairment in rule-governed behavior incorporating attentional set-shifting — a rodent model of the psychosis-like cognitive deficits associated with NMDA hypofunction
- **Absence of lethality at doses tested** (unlike 3-OH-PCP and 3-MeO-PCP)

### Class-Level Effects (PCP Parent; Bey & Patel 2007 [Ref 21])

Dose-response in humans (PCP reference data, not 3-Cl-PCP specific):

| Dose Range | Typical Effects |
|---|---|
| 2–5 mg | Euphoria, dissociation, ataxia, nystagmus, slurred speech, impaired judgment |
| 5–25 mg | Stupor, mild coma, bizarre posturing, psychosis, hallucinations, muscle contractions |
| >25 mg | Deep coma, seizures, severe hyperthermia, respiratory failure, death |

⚠️ **FLAG:** These dose ranges are for PCP (smoked/parenteral). 3-Cl-PCP potency relative to PCP is not established from human data. The seed data in the brief provides no dose ranges; community sources (PsychonautWiki, Tripsitter) cite dose tables that were not extractable in full due to page rendering limitations. The generation agent should treat any dose proposals as requiring editorial review.

### Effects Profile (Class-Level from PCP/Arylcyclohexylamine Literature)

Based on NMDA antagonism and sigma/dopamine pharmacology, expected effects include:

**Perceptual:** Visual distortion and hallucinations, spatial disorientation, derealization, double vision, visual drifting, altered depth perception — consistent with NMDA hypofunction in sensory cortex Jentsch and Roth (1999 [Ref 10])

**Cognitive:** Amnesia (working memory impairment), thought disorganization, delusions, cognitive euphoria, immersion/dissociation — Kapur and Seeman (2002 [Ref 11]); Shaw et al. (2024 [Ref 1])

**Physical:** Stimulation (monoamine reuptake inhibition component), motor control impairment, nystagmus, tachycardia, hypertension, analgesia, nausea, dizziness — Bey and Patel (2007 [Ref 21])

**Emotional:** Anxiety, euphoria, disinhibition, depersonalization — class effects

**Duration (class-level; PCP data):** Onset by inhalation/IV 2–5 min; oral 15–60 min. Duration varies markedly with dose and route; lipophilic redistribution means CNS effects can persist 7 hours to multiple days in chronic/high-dose users Bey and Patel (2007 [Ref 21]).

---

## Safety & Toxicity

### LD50 / Lethal Dose

**No LD50 data exists for 3-Cl-PCP in any species.**

For comparison, in silico toxicity modeling for PCP analogs (3-HO-PCP, 3-MeO-PCP, 4-MeO-PCP) estimates oral LD50 in rats at approximately **200–630 mg/kg** and IV LD50 in mice at approximately **25–59 mg/kg** Noga and Jurowski (2026 [Ref 8]). These in silico predictions carry significant uncertainty and are not validated for 3-Cl-PCP.

⚠️ **FLAG (Safety-critical):** Toxic dosage for 3-Cl-PCP is explicitly unknown (confirmed by brief seed data: "toxic dosage is unknown"). No human or animal lethality data exists.

### Organ Toxicity

**Rhabdomyolysis and acute kidney injury:** Documented for 3-methyl-PCP (closely related ring-substituted analog) by Deutsch et al. (2026 [Ref 7]), the first confirmed case of 3-methyl-PCP use. PCP-class drugs can cause hyperthermia, violent agitation, and sustained muscle contraction — all contributors to rhabdomyolysis. This represents a serious documented risk for the ring-substituted PCP class.

**Cardiovascular:** PCP-class NMDA antagonists produce sympathomimetic effects (tachycardia, hypertension) via catecholamine reuptake inhibition. In silico modeling for PCP analogs predicts hERG inhibition (IC₅₀ ~4.9–12.3 µM) suggesting QT prolongation risk Noga and Jurowski (2026 [Ref 8]). ⚠️ **FLAG:** Not validated for 3-Cl-PCP specifically.

**Neurotoxicity:** Chronic NMDA antagonist exposure is associated with Olney lesions (vacuolation of neurons in posterior cingulate/retrosplenial cortex) in rodents. The relevance to human use is debated. Long-term cognitive disturbance is documented for chronic ketamine users (frontal white matter abnormalities, cognitive deficits) — Mion and Villevieille (2013 [Ref in registry]).

**Hepatotoxicity:** In silico modeling predicts liver as a target organ (probability up to 0.91 for PCP analogs) Noga and Jurowski (2026 [Ref 8]).

### Psychological Risks

**Psychosis:** PCP is a well-established psychotomimetic. NMDA hypofunction produces schizophrenia-like positive, negative, and cognitive symptoms Jentsch and Roth (1999 [Ref 10]). 3-Cl-PCP produced dose-dependent psychosis-like neurocognitive deficits in a rat model specifically selected for validity against the human psychosis construct Shaw et al. (2024 [Ref 1]).

**Prolonged psychiatric sequelae:** Case reports for 3-MeO-PCP document hallucinations lasting up to 6 weeks post-exposure Stevenson and Tuddenham (2014 [Ref 33]). Similar prolonged effects may occur with 3-Cl-PCP given the shared pharmacological class.

**Violence:** Case report of attempted murder associated with 3-MeO-PCP + MDPV use Stevenson and Tuddenham (2014 [Ref 33]). PCP-class compounds are associated with agitated, violent behavior in acute intoxication states.

### Case Reports Specific to 3-Cl-PCP

**No published human case reports of 3-Cl-PCP intoxication exist in the peer-reviewed literature** as of the search date (May 2026). The forensic identification report from Slovenia (2020) confirms existence but does not document clinical outcomes CFSRE (2021 [Ref 31]).

---

## Harm Reduction

### Contraindications (Class-Level; No 3-Cl-PCP Specific Data)

1. **Pre-existing psychotic disorders:** NMDA antagonists exacerbate schizophrenia symptoms and are established psychotomimetics. Contraindicated in individuals with schizophrenia, schizoaffective disorder, or personal/family history of psychosis Jentsch and Roth (1999 [Ref 10]).

2. **Cardiovascular disease:** Sympathomimetic effects (tachycardia, hypertension) and potential QT prolongation represent significant risk Noga and Jurowski (2026 [Ref 8]).

3. **CNS depressant polydrug use:** Combining dissociatives with alcohol, benzodiazepines, opioids, or other CNS depressants carries synergistic risk for respiratory depression. Polydrug use was identified in 53% of ketamine-related fatalities in the systematic review Chaves et al. (2023 [Ref 29]).

4. **Stimulant polydrug use:** Combining NMDA antagonists with stimulants (amphetamines, cocaine) may produce unpredictable cardiovascular stress and psychiatric effects via compounded dopaminergic activation.

5. **Pregnancy/lactation:** No specific data; contraindicated by analogy with class.

### Testing and Identification

- Standard immunoassay urine drug screens **will not detect** novel PCP analogs including 3-Cl-PCP; standard PCP immunoassay may show false negative. GC-MS or LC-HRMS required for confirmation Luethi and Liechti (2020 [Ref 25]).
- Reagent colorimetric tests (Simon's, Mecke, Mandelin, Robadope) may provide presumptive identification but cannot distinguish 3-Cl-PCP from other arylcyclohexylamines.

### Emergency Response (Class-Level; PCP Protocols)

Based on PCP management guidelines Bey and Patel (2007 [Ref 21]):
- Chemical restraint preferred over physical restraint (reduces rhabdomyolysis risk)
- Benzodiazepines for sedation; avoid antipsychotics if hyperthermic
- Activated charcoal (1 g/kg) if recent oral ingestion
- Aggressive cooling if hyperthermia >40°C
- Cardiac monitoring; assess CPK/electrolytes for rhabdomyolysis
- Hemodialysis ineffective for drug removal but useful if AKI from rhabdomyolysis
- Acidification of urine historically used but evidence limited and risks acute tubular necrosis — modern guidelines do not recommend it

---

## Tolerance & Dependence

### Tolerance (Class-Level Data)

**Rapid tolerance development** has been demonstrated for PCP in multiple rodent models. Spain and Klingman (1985 [Ref 13]) demonstrated tolerance to PCP motor-impairing effects within 3.5 days of continuous IV infusion, with >2-fold rightward shift in dose-response curves. Chait and Balster (1978 [Ref 35]) demonstrated approximately 2-fold tolerance after 82–126 days of chronic dosing in squirrel monkeys.

**Brief DB seed data:** Tolerance buildup listed as "with prolonged and repeated use"; half-life 5.5 days; full reset 1.5 weeks. These values are sourced from community consensus (not published for 3-Cl-PCP specifically). They are plausible given the extended lipophilic redistribution of arylcyclohexylamines.

**Cross-tolerance:** Documented between PCP and sigma agonists (SKF-10047) Stafford et al. (1983 [Ref 30]), and expected with all dissociatives (ketamine, dextromethorphan, MXE, other NMDA antagonists). The brief lists cross-tolerance with dissociatives, consistent with class pharmacology.

### Dependence

**PCP physical dependence** has been demonstrated in rats after 7 days of continuous IV infusion; withdrawal syndrome included piloerection, audiogenic seizures, weight loss, reduced locomotor activity — Spain and Klingman (1985 [Ref 13]). Signs emerged 4 h after cessation, mostly resolved within 24 h.

**Brief DB seed data:** Physical dependence rated moderate; psychological dependence moderate; formation noted as "moderately addictive with high potential for adverse side effects such as psychosis." This is consistent with the PCP class literature. PCP has demonstrated self-administration (reinforcing properties) in animals, supporting genuine addictive potential Balster and Willetts (1988 [Ref 4]).

⚠️ **FLAG:** Dependence data for 3-Cl-PCP specifically is not published. All dependence characterization derives from PCP class data and the community consensus values in the brief.

---

## Interactions

**No published drug interaction data exists specifically for 3-Cl-PCP.** The following interactions are extrapolated from PCP and arylcyclohexylamine class pharmacology:

### High-Risk Combinations

1. **CNS Depressants (alcohol, benzodiazepines, opioids, GHB):** Additive CNS depression, respiratory depression, loss of consciousness. Polydrug use accounts for majority of dissociative-related deaths Chaves et al. (2023 [Ref 29]).

2. **Stimulants (amphetamines, cocaine, MDMA):** Combined dopaminergic activation may produce severe cardiovascular stress (hypertensive crisis), hyperthermia, and psychosis exacerbation.

3. **Tramadol / Serotonergic agents:** NMDA antagonists (especially at sigma-1 receptor) combined with serotonergic agents may increase serotonin syndrome risk, though direct evidence for 3-Cl-PCP is absent.

4. **Lithium:** Lithium combined with dissociatives increases risk of seizures. Known interaction for ketamine and MXE class Zanda et al. (2016 [Ref 28]).

5. **MAOIs:** Increased risk of serotonin toxicity via dopamine/monoamine reuptake inhibition component of PCP pharmacology combined with MAOI-induced monoamine accumulation.

### CYP Enzyme Interactions

3-Cl-PCP is expected to be metabolized primarily by **CYP2B6** (primary for PCP bioactivation and for ketamine N-demethylation) and **CYP3A4/CYP2C19** — Driscoll et al. (2007 [Ref 14]); Dinis-Oliveira (2017 [Ref 34]). CYP2B6 is **mechanism-based inactivated by PCP** itself Shebley and Hollenberg (2007 [Ref in registry]) — meaning 3-Cl-PCP may self-inhibit its own metabolism, contributing to accumulation with repeated dosing.

Strong CYP2B6 inhibitors (e.g., ticlopidine, voriconazole) could reduce metabolism and increase plasma levels. Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) could accelerate clearance.

⚠️ **FLAG (Safety-critical):** All interaction data is extrapolated from PCP parent compound. No published data on 3-Cl-PCP CYP interactions or clinical drug interactions exists.

---

## Legal Status

### United States

3-Cl-PCP is **not specifically listed** in the DEA Controlled Substances Act schedules. However, as a structural analog of PCP (a Schedule II controlled substance), it is subject to **21 U.S.C. § 813 (Federal Analog Act)** when intended for human consumption — making it effectively a Schedule I controlled substance for purposes of manufacture, distribution, and possession with intent to distribute. Web search confirmed no specific DEA scheduling action for 3-Cl-PCP [Ref 17, 18].

### United Kingdom

3-Cl-PCP is covered by the **Psychoactive Substances Act 2016**, which bans all psychoactive substances (with exemptions for alcohol, tobacco, caffeine, food, and controlled medicines). Supply, production, and importation are criminal offenses. It is not separately listed in the Misuse of Drugs Act 1971 schedules [Ref — web search: UK legislation].

### Hungary

**Explicitly illegal since April 2021** Tripsitter (2023 [Ref 19]).

### International

Not under international control via the UN 1971 Convention on Psychotropic Substances. PCP and named analogs (PCE, PHP, PCPY, TCP) are in Schedule I of the 1971 Convention; 3-Cl-PCP is not named UNODC (2024 [Ref 17]).

**Regulatory precedent:** The DEA permanently scheduled 3-MeO-PCP in Schedule I (effective April 22, 2026) following a proposed rule in June 2025 DEA Federal Register (2026 [Ref 18]). This represents the most recent scheduling action for a ring-substituted PCP analog and signals regulatory attention to this compound class.

⚠️ **FLAG:** Legal status in Australia, Canada, Germany, and other EU member states was not confirmed. Legal status is rapidly evolving for this compound class.

---

## Clinical Trials

**No clinical trials involving 3-Cl-PCP have been registered on ClinicalTrials.gov.** Search returned zero results [clinical trial search, step 10]. No therapeutic applications have been proposed or studied.

---

## Community Feedback Analysis

**No community feedback was submitted for 3-Cl-PCP (Part A2 of the brief is empty).**

No contributor corrections, dose range reports, or editorial observations are available for this substance. The research output therefore relies entirely on the published scientific literature and secondary sources.

---

## Gaps & Flags

### Critical Data Absent from Published Literature

1. **No substance-specific binding affinity (Ki/IC50) data** for 3-Cl-PCP at any receptor (NMDA, sigma-1, sigma-2, D1, D2, DAT, SERT, NET). All receptor pharmacology is extrapolated from PCP parent compound.

2. **No published human case reports or clinical observations** of 3-Cl-PCP intoxication. Forensic identification was documented in Slovenia (2020) but clinical outcome data is absent.

3. **No human pharmacokinetic data** (half-life, Vd, Tmax, bioavailability, Cmax) published for 3-Cl-PCP specifically.

4. **No LD50 or dose-response toxicity data** in any species for 3-Cl-PCP. Toxic dose is explicitly unknown.

5. **SMILES string not returned by PubChem API** — should be retrieved directly from CID 125502037. InChIKey and formula are confirmed.

6. **CAS number not confirmed** via any verified source.

7. **No dose range data from controlled studies** — brief seed data has no dose values; PsychonautWiki/Tripsitter dose tables were not fully extractable due to rendering limitations.

8. **Stereochemistry:** 3-Cl-PCP lacks a chiral center at the phenyl/cyclohexyl junction in the same way PCP does (the junction carbon bears the piperidine N, not H, so stereochemistry considerations differ from ketamine). The InChIKey (HUHBTESMMFLCAN-UHFFFAOYSA-N) contains no stereo descriptor, consistent with a single stereoisomeric form. No enantiospecific data exists.

9. **Metabolic pathway for 3-Cl-PCP specifically:** The chlorine substituent at meta-position will alter hydroxylation patterns. No published in vitro metabolic studies exist.

### Safety-Critical Unresolved Items

- **Dose ranges** (threshold, light, moderate, strong) proposed in any article would be based on structural analog inference from PCP, not substance-specific human data. Must be flagged prominently for editorial review.
- **LD50 / toxic dose:** Completely unknown. Any quantitative toxicity threshold is extrapolated from in silico PCP analog modeling.
- **Interaction severity ratings** are class-level inferences with no 3-Cl-PCP-specific evidence.
- **Cardiovascular risk:** hERG inhibition prediction (in silico, for related analogs) not validated for 3-Cl-PCP.

### Source Quality Notes

- **Shaw et al. 2024 [Ref 1]** is the single published peer-reviewed primary study of 3-Cl-PCP. It is a rodent study; human translation requires caution.
- **All other pharmacological data** is class-level from PCP, ketamine, or other arylcyclohexylamine analogs.
- **Secondary sources** (PsychonautWiki, Tripsitter) are included for historical context only; not used for any pharmacological or dosing claims.
- **In silico toxicity predictions** (Noga & Jurowski 2026 [Ref 8]) provide order-of-magnitude estimates but are not validated for 3-Cl-PCP.